A practical reference on Phase 3 trial: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-13 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Formation of secondary structures is a strong indication of increased stability within the protein, and only one combination of secondary structures assumed by the polypeptide backbone will have the lowest energy and therefore be present in the native state of the protein. Among the first structures to form once the polypeptide begins to fold are alpha helices and beta turns, where alpha helices can form in as little as 100 nanoseconds and beta turns in 1 microsecond. There exists a saddle point in the energy funnel landscape where the transition state for a particular protein is found. The transition state in the energy funnel diagram is the conformation that must be assumed by every molecule of that protein if the protein wishes to finally assume the native structure. No protein may assume the native structure without first passing through the transition state. The transition state can be referred to as a variant or premature form of the native state rather than just another intermediary step. The folding of the transition state is shown to be rate-determining, and even though it exists in a higher energy state than the native fold, it greatly resembles the native structure. Within the transition state, there exists a nucleus around which the protein is able to fold, formed by a process referred to as "nucleation condensation" where the structure begins to collapse onto the nucleus.
Japan has the highest number of 7-Eleven locations in the world, as of the company's 85,000+ stores around the globe, 21,668 stores (nearly 25% of global stores) are in Japan, with 2,824 stores in Tokyo alone. Japanese 7-Eleven stores often bear the name of its holding company Seven & I Holdings—in fact, Seven & I's subsidiary Seven-Eleven Japan, the master franchisee for Japan, is the direct parent company of 7-Eleven, Inc. On September 1, 2005, Seven & i Holdings Co., Ltd., a new holding company, became the parent company of 7-Eleven, Ito-Yokado, and Denny's Japan. As of July 2019, 7-Eleven has stores in all 47 prefectures of Japan with the opening of 14 new locations in Okinawa Prefecture. The aesthetics of the store are somewhat different from that of 7-Eleven stores in other countries as the stores offer a wider selection of products and services. 7-Eleven stores in Japan are also popular among tourists from other countries, as the Seven Bank automated teller machines at branches will accept foreign debit and credit cards for withdrawing cash in Japanese yen. Following the example of other convenience stores in Japan, 7-Eleven has solar panels and LEDs installed in about 1,400 of its stores. In July 2019, 7-Eleven launched then almost immediately suspended a mobile payment service, 7pay. The service was hacked upon launch, and attackers were able to spend money from affected customers' accounts.
By the early 1940s, the Soviet economy had become relatively self-sufficient; for most of the period until the creation of Comecon, only a tiny share of domestic products was traded internationally. After the creation of the Eastern Bloc, external trade rose rapidly. However, the influence of the world economy on the USSR was limited by fixed domestic prices and a state monopoly on foreign trade. Grain and sophisticated consumer manufactures became major import articles from around the 1960s. During the arms race of the Cold War, the Soviet economy was burdened by military expenditures, heavily lobbied for by a powerful bureaucracy dependent on the arms industry. At the same time, the USSR became the largest arms exporter to the Third World. A portion of Soviet resources during the Cold War were allocated in aid to the Soviet-aligned states. The Soviet Union's military budget in the 1970s was gigantic, forming 40–60% of the entire federal budget and accounting to 15% of the USSR's GDP (13% in the 1980s). From the 1930s until its dissolution in late 1991, the way the Soviet economy operated remained essentially unchanged. The economy was formally directed by central planning, carried out by Gosplan and organized in five-year plans. However, in practice, the plans were highly aggregated and provisional, subject to ad hoc intervention by superiors. All critical economic decisions were taken by the political leadership. Allocated resources and plan targets were usually denominated in rubles rather than in physical goods. Credit was discouraged, but widespread.
== Usage == Zinc L-carnosine has been used orally or as an oral rinse, lozenge or suppository. The typical clinical oral dose is 150 mg/day, containing 34 mg zinc and 116 mg L-carnosine. (The Tolerable Upper Intake Level (UL) for total zinc intake from all sources in adults is 40 mg/day.) As an oral rinse, it has been used three to four times a day, with or without swallowing, providing a total amount of 150 mg/day. A solution of 5% sodium alginate has been used. Alternatively, it has been used as a lozenge containing 18.75 mg, four times a day. It has also been used as a suppository of 75 mg with Witepsol as a base.
Sources: en.wikipedia.org
=== Executive Overhaul (June 1–2, 2026) === Following a week-long emergency meeting that resulted in severe disciplinary measures against internal dissenters, the council held its 4th Extraordinary Session on June 1, 2026. The assembly unanimously approved an entirely restructured organizational layout for regional bureaus. Debretsion submitted a slate of senior appointments, highlighted by swearing in TPLF Vice Chairperson Amanuel Assefa as Deputy President and Head of the Justice Bureau.
== Collaborations == In 2013, La Colombe partnered with the Clinton Foundation to found the Haiti Coffee Academy. The organization's stated aim is to improve coffee growers’ livelihoods in Haiti through training programs for smallholder farmers, a demonstration farm and nursery, and efforts to strengthen the supply chain for both local and export markets for Haitian coffee. In 2016, La Colombe collaborated with Yards Brewing Company, also in the Philadelphia area, to produce a coffee stout to be served in local Shake Shack branches. Also in 2016, the company collaborated with the Icelandic brewer Einstök and again with Yards on Snorri's Awakening, a coffee pale ale. In 2021, the company collaborated with Whole Foods Market to open new stores in New York City and Austin.
=== Blockade for diseases with a chronic immunological component === As increasingly documented, the SP-NK1R system induces or modulates many aspects of the immune response, including WBC production and activation, and cytokine expression, Reciprocally, cytokines may induce expression of SP and its NK1R. In this sense, for diseases in which a pro-inflammatory component has been identified or strongly suspected, and for which current treatments are absent or in need of improvement, abrogation of the SP-NK1 system continues to receive focus as a treatment strategy. Currently, the only completely developed method available in that regard is antagonism (blockade, inhibition) of the SP preferring receptor, i.e., by drugs known as neurokinin type 1 antagonists (also termed: SP antagonists, or tachykinin antagonists.) One such drug is aprepitant to prevent the nausea and vomiting that accompanies chemotherapy, typically for cancer. With the exception of chemotherapy-induced nausea and vomiting, the patho-physiological basis of many of the disease groups listed below, for which NK1RAs have been studied as a therapeutic intervention, are to varying extents hypothesized to be initiated or advanced by a chronic non-homeostatic inflammatory response.
There have been few incidents of doping in football, mainly because of little unannounced testing relative to the high amount of professionals. There is also a lack of further investigation (e.g. Tony Schumacher revelations and the still unknown footballers of Eufemiano Fuentes), preservation of samples, and consequences. In 2014, the biological passport was introduced in the 2014 FIFA World Cup; blood and urine samples from all players before the competition and from two players per team and per match are analysed by the Swiss Laboratory for Doping Analyses.
On September 25, Xi and Peng returned to the White House with Donald and Melania Trump. They then attended a tea ceremony in the Red Room. Trump said US farmers "are going to be very happy" with the talks, adding "A lot of very positive things happened, but America is very happy about this visit and I’m sure China is very happy also". He said "We’ve had a tremendous visit from two spectacular people" and "We’ve really enjoyed it and I think we’ve been tremendous strides. We’ve made great strides, very positive for both countries." During this tea ceremony, Xi said that he and Trump "are like two people who are charting the course for the great ship of China-U.S. relations." Xi also confirmed that two leaders will to see each other later this year in twice, including APEC summit in Shenzhen and G20 Summit in Miami. Later, Xi and Trump visited the National Archives, and viewed the Declaration of Independence, the Constitution and the Bill of Rights. According to the NPR, a table that included a temporary display showcasing a brick from the Great Wall of China and an 19th century scroll sent by a Qing emperor was removed because the display also planned to show the Treaty of San Francisco, which China considers as illegitimate because it was not a signatory. Other documents, including Six Assurances and the Three Communiqués, were also discussed for display, but ultimately not included.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.